Vectura Group plc Board Appointments (0490K)
December 30 2020 - 1:00AM
UK Regulatory
TIDMVEC
RNS Number : 0490K
Vectura Group plc
30 December 2020
Vectura Group appoints Jeanne Hecht and Jeanne Thoma to its
Board of Directors
Chippenham, UK - 30 December 2020: Vectura Group plc (LSE: VEC)
("Vectura", the "Group", or the "Company"), an industry-leading
specialist inhalation CDMO, is pleased to announce the appointments
of Jeanne Hecht and Jeanne Thoma as Independent Non-Executive
Directors of the Company with effect from 31(st) December 2020.
Jeanne Hecht was most recently CEO of Ora, Inc. ("Ora") a
full-service pre-clinical and clinical ophthalmic drug and device
development firm. Previously she served as Chief Operating Officer
and was a Board Director of Median Technologies, a clinical
services imaging business. Prior to this Jeanne had a substantial
career with Quintiles (later IQVIA), the world's largest contract
development services company, where she led global sales and
strategic accounts.
Jeanne Thoma was most recently CEO and President of SPI Pharma,
which provides specialist formulation and ingredient services to
the pharmaceutical and nutritional industries, and is part of
Associated British Foods plc. Previously she served as a senior
advisor to the pharmaceutical industry, and has had successful
careers with Lonza where, in her last role, she was President and
Executive Committee Member, and BASF where she served in senior key
commercial roles in their pharmaceutical solutions business. Jeanne
is a member of the Boards of Directors of ANI Pharmaceuticals Inc,
an integrated specialty pharmaceutical company, and Avid
Bioservices Inc, a contract development and manufacturing
organisation focused on the development and cGMP manufacturing of
biopharmaceutical mammalian cell culture products.
Bruno Angelici, Chairman of Vectura, commented:
"I'm delighted to welcome Jeanne Hecht and Jeanne Thoma to the
Board of Vectura. Jeanne Hecht brings significant experience in
drug development services globally, which directly supports our new
strategic direction as a leading inhalation CDMO. Jeanne Thoma
brings a unique blend of commercial, HR and business leadership
experience in pharmaceutical services, which will bring new domain
expertise to our Board supporting our new business model."
Commenting on her appointment, Jeanne Hecht, said:
"I am pleased to join the Board of Vectura at this exciting time
and look forward to helping the Board build on the Company's
position as a leading development services business, helping the
business deliver significant benefits to a growing number of
customers and their patients."
Jeanne Thoma, said:
"As Vectura continues to build on its position as a leading
inhalation specialist CDMO, I am excited to be working with the
Board to help contribute to the Company's future growth."
There are no additional details to disclose under Listing Rule
9.6.13 (1) to (6) in respect of either appointment.
- Ends -
For more information, please contact:
Vectura Group plc
David Ginivan - VP Corporate Communications +44 (0)7471 352 720
Elizabeth Knowles - Director Investor Relations +44 (0)7767 160 565
Consilium Strategic Communications +44 (0)20 3709 5700
Mary-Jane Elliott / Susan Stuart / David Daley
About Vectura
Vectura is a provider of innovative inhaled drug delivery
solutions that enable partners to bring their medicines to
patients. With differentiated proprietary technology and
pharmaceutical development expertise, Vectura is one of the few
companies globally with the device, formulation and development
capabilities to deliver a broad range of complex inhaled
therapies.
Vectura has ten key inhaled and eleven non-inhaled products
marketed by partners with global royalty streams, and a diverse
partnered portfolio of drugs in clinical development. Our partners
include Hikma, Novartis, Sandoz (a division of Novartis AG),
Mundipharma, Kyorin, GSK, Bayer, Chiesi, Almirall, and Tianjin
KingYork.
For further information, please visit Vectura's website at
www.vectura.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOABUBDDCDDDGGC
(END) Dow Jones Newswires
December 30, 2020 02:00 ET (07:00 GMT)
Vectura (LSE:VEC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vectura (LSE:VEC)
Historical Stock Chart
From Apr 2023 to Apr 2024